Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.33 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6009983 | 0.71 | RAD52 (0.38) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL5500474 | 0.71 | DPP4 (0.35) | EPHX2L3MBTL1HSD11B1 | |
| SCHEMBL6008625 | 0.71 | EPHX2 (0.38) | SMN1; SMN2EPHX2 | |
| SCHEMBL6009446 | 0.70 | RAD52 (0.40) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL1778693 | 0.70 | SMN1; SMN2 (0.61) | LMNASMN1; SMN2EPHX2L3MBTL1TDP1 | |
| SCHEMBL9298062 | 0.69 | FDPS (0.41) | LMNASMN1; SMN2EPHX2L3MBTL1TDP1 | |
| SCHEMBL1073954 | 0.67 | LMNA (0.48) | LMNASMN1; SMN2EPHX2L3MBTL1TDP1 | |
| SCHEMBL5503709 | 0.65 | EPHX2 (0.36) | LMNASMN1; SMN2EPHX2L3MBTL1TDP1 | |
| SCHEMBL5504957 | 0.64 | — | — | |
| SCHEMBL18747650 | 0.63 | LMNA (0.46) | LMNASMN1; SMN2EPHX2L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | LMNA 50/4885SMN1; SMN2 141/4885EPHX2 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.